Asset Details
Do you wish to reserve the book?
Serological Correlate of Protection against Norovirus-Induced Gastroenteritis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Serological Correlate of Protection against Norovirus-Induced Gastroenteritis
Do you wish to request the book?
Serological Correlate of Protection against Norovirus-Induced Gastroenteritis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Serological Correlate of Protection against Norovirus-Induced Gastroenteritis
2010
Overview
Background. Norovirus infection is the leading cause of acute nonbacterial gastroenteritis. Histoblood group antigens (HBGAs) are host susceptibility determinants for Norwalk virus (NV) infection. We hypothesized that antibodies that block NV-HBGA binding are associated with protection from clinical illness following NV exposure. Methods. We developed an HBGA blocking assay to examine the ability of human serum to block the interaction of NV viruslike particles with H type 1 and H type 3 glycans. Serum samples from persons who were experimentally challenged with NV were evaluated. Results. There was a high correlation between the H type 1 and H type 3 synthetic glycan assays (r=0.977; P<.001); the H type 1 assay had higher quantitative sensitivity (P<.001). Among 18 infected secretor-positive individuals, blocking titers peaked by day 28 after challenge and were higher for individuals who did not develop gastroenteritis than for those who developed gastroenteritis on days 0, 14, 28, and 180 (P<.05 for each). In addition, 6 of 6 subjects without gastroenteritis had measurable prechallenge blocking titers (>25), compared with 2 of 12 subjects with gastroenteritis (P=.002). Conclusions. Blocking antibodies correlate with protection against clinical NV gastroenteritis. This knowledge will help guide the evaluation of new vaccine strategies and the elucidation of the nature of immunity to the virus. Trial registration. ClinicalTrials.gov identifier: NCT00138476.
Publisher
University of Chicago Press,Oxford University Press
Subject
/ Adult
/ Antibodies, Blocking - blood
/ Antibodies, Blocking - immunology
/ Antigens
/ Biological and medical sciences
/ Caliciviridae Infections - blood
/ Caliciviridae Infections - immunology
/ Diseases
/ Enzyme linked immunosorbent assay
/ Fundamental and applied biological sciences. Psychology
/ Gastroenteritis - immunology
/ Humans
/ Polysaccharides - immunology
/ Virology
/ Viruses
